Validation of an economic model of paliperidone palmitate for chronic schizophrenia

References

• Graham CN, Mauskopf JA, Lawson AH, et al. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health 2012;15:55-64
   PubMed Web of Science ®Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al; ISPOR–SMDM Modeling Good Research Practices Task Force. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health 2012;15:843-50
   PubMed Web of Science ®Google Scholar
• Kopec JA, Finès P, Manuel DG, et al. Validation of population-based disease simulation models: a review of concepts and methods. BMC Public Health 2010;10:710
   PubMed Web of Science ®Google Scholar
• Barnett PG, Scott JY, Krystal JH, et al; CSP 555 Research Group. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry 2012;73:696-702
   PubMedGoogle Scholar
• Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011;10:10
   PubMed Web of Science ®Google Scholar
• Knapp M, Windmeijer F, Brown J, et al; SOHO Study Group. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics 2008;26:341-58
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Swartz M, McEvoy J, et al. Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Rev Pharmacoecon Outcomes Res 2007;7:103-11
   PubMedGoogle Scholar
• Barnett PG, Scott JY, Rosenheck RA; CSP 555 Study Group. How do clinical trial participants compare to other patients with schizophrenia? Schizophr Res 2011;130:34-9
   PubMed Web of Science ®Google Scholar
• Berntsson A, Einarson TR, Eriksson L, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Presented at the 53rd Annual Meeting of the Scandinavian College of Neuro-Psychopharmacology, Copenhagen, Denmark, April 25–27, 2012
   Google Scholar
• O’Sullivan A, Thompson D. Country-to-country adaptation of pharmacoeconomic research: methodologic challenges and potential solutions. http://www.ispor.org/news/articles/feb09/ctc.asp. Accessed 20 Feb 2013
   Google Scholar
• Sweden inflation rate (consumer prices). http://www.indexmundi.com/sweden/inflation_rate_(consumer_prices).html. Accessed 29 Sept 2012
   Google Scholar
• Asseburg C, Willis M, Löthgren M, et al. Hospitalisation utilisation and costs in schizophrenia patients in finland before and after initiation of risperidone long-acting injection. Schizophr Res Treatment 2012; 2012:791468
   PubMedGoogle Scholar
• Beard SM, Maciver F, Clouth J, et al. A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. Eur J Health Econ 2006;7:165-72
   PubMedGoogle Scholar
• Carswell C, Wheeler A, Vanderpyl J, et al. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig 2010;30:777-87
   PubMed Web of Science ®Google Scholar
• Heeg B, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005;23(1 Suppl):17-33
   PubMedGoogle Scholar
• Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull 2002;28:589-605
   PubMed Web of Science ®Google Scholar
• Kim K, Aas E. Cost-effectiveness analysis of olanzapine and risperidone in Norway. J Ment Health Policy Econ 2011;14:125-35
   PubMed Web of Science ®Google Scholar
• Law WL, Hui HY, Young WM, et al. Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients–a cost analysis. Int J Clin Pharmacol Ther 2007;45:264-70
   PubMed Web of Science ®Google Scholar
• Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract 2007;61:1979-88
   PubMed Web of Science ®Google Scholar
• Phanthunane P, Vos T, Whiteford H, et al. Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. Cost Eff Resour Alloc 2011;9:6
   PubMedGoogle Scholar
• Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54:453-63
   PubMed Web of Science ®Google Scholar
• Spill B, Silvia Konoppa S, Kissling W, et al. Long-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract 2010;14:53-62
   PubMed Web of Science ®Google Scholar
• Taylor D, Hayhurst K, Kerwin R. A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia. Int Clin Psychopharmacol 2007;22:133-6
   PubMed Web of Science ®Google Scholar
• Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 2009;120:97-101
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9
   PubMed Web of Science ®Google Scholar
• Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006;114:14-20
   PubMed Web of Science ®Google Scholar
• Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011;3:9-14
   PubMedGoogle Scholar
• Castro-Costa E, Andrade JM, Quites L. Long-acting injectable risperidone improves quality of life in schizophrenic patients: a clinical case series. Rev Bras Psiquiatr 2008;30:403-4
   PubMed Web of Science ®Google Scholar
• Chang HC, Tang CH, Tsai SJ, et al. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan. J Clin Psychiatry 2009;70:141
   PubMed Web of Science ®Google Scholar
• Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24
   PubMedGoogle Scholar
• Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(1 Suppl):75-89
   PubMedGoogle Scholar
• Einarson TR, Geitona M, Chaidemenos A, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry 2012;11:18
   PubMed Web of Science ®Google Scholar
• Laux G, Heeg B, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23(1 Suppl):49-61
   PubMed Web of Science ®Google Scholar
• Llorca PM, Miadi-Fargier H, Lançon C, et al. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Encephale 2005;31:235-46
   PubMed Web of Science ®Google Scholar
• Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010;26:501-9
   PubMed Web of Science ®Google Scholar
• Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci 2005;59:385-94
   PubMed Web of Science ®Google Scholar
• Yang L, Li M, Tao LB, et al. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health 2009;12(3 Suppl):S66-9
   Google Scholar
• Mehnert A, Nicholl D, Pudas H, et al. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ 2012;15:844-61
   PubMedGoogle Scholar
• Hensen M, Heeg B, Löthgren M, et al. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy 2010;8:327-41
   PubMedGoogle Scholar
• Willis M, Svensson M, Löthgren M, et al. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ 2010;11:585-94
   PubMed Web of Science ®Google Scholar
• Lindström E, Eberhard J, Fors BM, et al. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry 2011;65:403-13
   PubMed Web of Science ®Google Scholar
• Edwards NC, Muser E, Doshi D, et al. The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving. J Med Econ 2012;15:623-34
   PubMedGoogle Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27:713-30
   PubMed Web of Science ®Google Scholar
• Edwards NC, Rupnow MF, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005;23:299-314
   PubMed Web of Science ®Google Scholar
• Chang HC, Tang CH, Huang ST, et al. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. J Psychiatr Res 2012;46:751-6
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7
   PubMed Web of Science ®Google Scholar
• Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007;116:36-46
   PubMed Web of Science ®Google Scholar
• Olivares JM, Peuskens J, Pecenak J, et al; e-STAR Study Group. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
   PubMed Web of Science ®Google Scholar
• Ren XS, Crivera C, Sikirica M, et al. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. J Clin Pharm Ther 2011;36:383-9
   PubMed Web of Science ®Google Scholar
• Su KP, Chang HC, Tsai SJ, et al. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Value Health 2009;12(Suppl):S118-21
   PubMedGoogle Scholar
• Taylor M, Currie A, Lloyd K, et al. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 2008;22:128-31
   PubMed Web of Science ®Google Scholar
• Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74
   PubMed Web of Science ®Google Scholar
• Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in “revolving door” schizophrenic patients. J Clin Psychiatry 1996;57:337-45
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Furiak NM, Lawson AH, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ 2012;15:531-47
   PubMedGoogle Scholar
• Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008;24:3341-55
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Stensland MD, Peng X, et al. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Curr Med Res Opin 2011;27:115-22
   PubMed Web of Science ®Google Scholar
• De Ridder A, De Graeve D. Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach. Pharmacoeconomics 2009;27:69-80
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc 2009;7:4
   PubMedGoogle Scholar
• Chue PS, Heeg B, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23(1 Suppl):62-74
   PubMedGoogle Scholar
• De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005;23(1 Suppl):35-47
   PubMedGoogle Scholar
• Lecomte P, De Hert M, van Dijk M, et al. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health 2000;3:1-11
   PubMedGoogle Scholar
• Mehnert A, Diels J. Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry - Mental Health Policy and Economics; Venice, Italy, March 25-27, 2011
   Google Scholar